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Summary 
Leukotriene B 4 (LTB4) is a chemotactic and cell-activating factor present at inflammatory sites 
in a variety of autoimmune diseases including multiple sclerosis  (MS). In this study, we used a 
murine model of MS,  experimental allergic encephalomyelitis (EAE), to assess the potential 
role ofLTB  4 on cell infiltration and paralysis. Injection ofencephalogenic T cells into naive an- 
imals induced paralysis and weight loss that was completely inhibited by treatment with the se- 
lective LTB  4 receptor antagonist CP-105,696 (EDs0 =  8.6 mg/kg orally). Although migration 
of lymphocytes into the central nervous system was unaffected, the efficacious effects of CP- 
105,696 correlated with up to a 97% decrease in eosinophil infiltration into the lower spinal 
cord as determined by light and electron microscopy and quantitated by levels of the specific 
enzyme marker eosinophil peroxidase. These results demonstrate that eosinophil recruitment in 
EAE is dependent on LTB  4 receptor ligation and further reveal a previously unrecognized role 
for eosinophils in the pathogenesis of this disease. 
xperimental allergic encephalomyelitis (EKE) is an in- 
']ammatory disease of  the central nervous system (CNS) 
myelin with  pathological  similarities  to  multiple  sclerosis 
(MS) (1-3). The immunological effector cells responsible for 
initiating the disease  have been shown, with depletion ex- 
periments, to be CD4 + lymphocytes (4). Once these enceph- 
alogenic T  cells migrate into the CNS, they are stimulated 
to release proinflammatory cytokines (5)  and chemokines 
(6), which recruit inflammatory cells,  compromise the in- 
tegrity of the blood-brain barrier, and stimulate the release 
of mediators that break down myelin, resulting in impaired 
nerve conduction and paralysis  (1, 3). 
The mediators involved in the pathogenesis of EKE and 
MS  are unclear. Products of the 5-lipoxygenase pathway, 
specifically leukotriene B4  (LTB4)  (7,  8),  have  been  de- 
tected in the spinal fluid of MS patients (9) and have been 
suggested to play a role in the pathogenesis of EAE (10). In 
addition to having direct chemoattractant activity (11, 12), 
LTB4 can modulate the activity oflymphocytes (7), raising 
the possibility that it might act on encephalogenic T cells in 
the CNS and enhance their ability to release mediators im- 
portant  for disease  progression.  In  this  study,  we  deter- 
mined the effects of the specific LTB  4 receptor antagonist 
CP-105,696 (13--15)  on disease pathology and cell-specific 
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infiltration into the spinal  cord of mice injected with anti- 
gen-specific encephalogenic T cells. 
Materials and Methods 
Reagents.  The  LTB  4 receptor antagonist  CP-105,696  was 
synthesized as previously described (15). RPMI medium supple- 
mented with 10 mM Hepes buffer, 100 U/ml penicillin-streptomy- 
cin, 0.1 mM nonessential amino acids, 2 mM t-glutamine,  1 mM 
sodium pyruvate, and 0.05 mM 2-ME was used for culturing T 
cells. All  components  were  obtained  from BioWhittaker  Inc. 
(Walkersville, MD). 
Encephalogenic Protein.  A previously described encephalogenic 
peptide  (acetyI-FFKNIVTPI~TPPP-amide)  (16) corresponding 
to regions 91-103 of guinea pig myelin basic protein was pre- 
pared by the Protein Chemistry Division at Pfizer, Inc. All re- 
agents were characterized by electrospray mass spectra (Firmegan 
TSQ-700) and amino acid analysis (ABI 420A) and were found 
to have had a single peak by reverse-phase HPLC. 
Animals.  Female SJL mice were obtained from The Jackson 
Laboratory (Bar Harbor, ME) at 6--8 wk of  age. Animals were ac- 
climated in-house for a minimum of 2 wk before use and were 
allowed food and water ad lib. Animals were routinely checked 
for pathogens and were always kept in microisolator cages. 
Passive Transfer Model of EAE.  EKE  was  induced in animals 
using  the  passive transfer model as  previously  described  (17). 
Mice were immunized in three separate areas on the lower back 
once a week for 2 wk with an emulsion containing 30 Izg H37RA 
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Detroit,  MI), 75 I~I  PBS, 75 I~I  IFA (0639-60-6;  Difco Laborato- 
ries  Inc.,  Detroit,  MI) and 75 l~g of  the encephalogenic peptide. 
Spleens or lymph nodes (inguinal,  brachial,  and axilhry)  were 
collected  7 d after  the last  immunization. A single-cell  suspemion 
was made, and cells  were placed  into  culture  using T-225 flasks 
(Costar  Corp., Cambridge, MA) for 4 d at a density  of  3 X  106 
cells/ml  in RPMI  medium containing  10% FCS and 5 ~g/m.1  of 
the encephalogenic peptide.  Cells  were also  plated  into  96-well 
plates  to determine proliferative  responses  to the antigen  over the 
4-d period using [3H]thymidine incorporation  as a guide.  After 
the culture  period,  the cells  were collected,  layered  over Histo- 
paque (1077-I;  Sigma Chemical Co.,  St.  Louis,  MO), and centri- 
fuged at 800 g for 15 rain.  Lymphocytes were then collected, 
washed,  adjusted  to 2.5 X  108 lymphobhsts/ml  in PBS  (the 
lymphoblasts were confirmed by FACS  | analysis  to be CD4 + 
IL-2R  + cells).  200 I~I  of  the cell  suspemion was then injected  in- 
traperitonealIy  into  naive mice.  Unless  otherwise  indicated,  CP- 
105,696 was orally administered on a daily basis beginning at the 
time of T cell injection. 
Paralysis was monitored on a daffy basis according to the fol- 
lowing criteria: (a), limp tail; (b), hind limb weakness;  (c), one 
hind limb paralyzed; (d), both hind limbs paralyzed; (e), mori- 
bund;  (f), death. Each group contained a minimum of five ani- 
mals and were allowed access to food and water at the cage base. 
Moribund  animals were  killed. The  mean  disease severity for 
each group was plotted over the study period, and the area under 
the curve was calculated. The percent inhibition of disease sever- 
ity was then calculated compared with the placebo-treated con- 
trois.  The  animal weight was  also  determined at various time 
points during the course of disease. 
Biochemical Measurements.  The selective eosinophil enzyme, eo- 
sinophil peroxidase (EPO), was measured as previously described 
(18).  Spinal cords were homogenized, subjected to two freeze- 
thaw cycles, and centrifuged at 1,000 g for 30 min. As a standard, 
serial dilutions of a lysed suspension of 2.5 X  104 eosinophils/ml 
were used. 
Microscopic Studies.  Samples for  light microscopy were  pre- 
pared by removing brain and selected portions of the spinal cord 
and fixing by immersion in  10%  neutral-buffered formalin for 
12-18 h. The fixed specimem were trimmed, processed, and em- 
bedded in paraflSn using standard techniques. 5-1~m thick sections 
were cut on a microtome (Autocut; R.eichert Jung, Vienna, Aus- 
tria), stained with hematoxylin and eosin, and viewed with a mi- 
croscope (FXA; Nikon Inc., Melville, NY). 
Samples for dectron microscopic examination were prepared 
by removing small portions of the formalin-fixed spinal cord and 
fixing for 1 h by immersion in 3% glutaraldehyde in 0.1  M  so- 
dium cacodylate buffer (pH 7.2, 4~  The tissue was then pro- 
cessed and embedded in epoxy resin. Thin sections were cut on a 
ultramicrotome (model FC-4, 1Leichert Jung), stained with ura- 
nyl acetate, and viewed on an electron microscope (model 1200; 
JEOL USA, Peabody, MA). 
Statistics.  The results are expressed as the mean -+ 1 SD. Sta- 
tistical analysis was done using the Student's t test and the Mann- 
Whimey U  test. A  P value of <0.05 was considered significant. 
The area under the curve was calculated using the trapezoidal rule. 
Results 
The paralysis induced in mice after the administration of 
encephalogenic T  cells could be completely prevented by 
the administration of a 20-mg/kg dose of the LTB4 recep- 
tor antagonist CP-105,696  (Fig.  1). At a lower dose of 10 
mg/kg, disease severity was reduced by up to three disease 
scores or 65% at day 38. The serum level of CP-105,696 18 h 
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Figure  1.  Effect  of CP-105,696 on the develop= 
ment of EKE. Naive mice were injected intraperi= 
toneally with encephalogenic T cells. Immediately 
after injection, animals received 15 daffy oral treat- 
ments with CP=105,696. Disease was  monitored 
for 30 d. This study is representative of  three studies 
using five animals per group. Solid circles, placebo; 
open  circles, 10 mg/kg CP-105,696;  open  trim= 
gles, 20 mg/kg CP-105,696. Significance was ob- 
tained beginning on day 6. 
1894  Leukotriene B4 in Experimental Allergic Encephalomyehtis Table 1.  Effect  of CP-105,696 on the Development of EAE 
after Passive Transfer 
Inhibition  Day of  Maximum 
Dose  of  Disease  onset  severity 
mg  lkg  % 
20.0  91.4 +- 7.4*  >18 +  8*  0.6 +  0.6* 
10.0  50.0 +- 5.0*  7.3 -+ 0.7  2.6 -+ 0.5 
1.0  No effect  6.8 +  0.8  3.4 
0.1  No effect  7.0 +- 0.8  3.3 
Placebo  0  7.5 +- 2.0  3.7 +- 1.3 
The data represent a total of  three studies using a minimum office ani- 
mah per group. Treatments were administered per os daily for 15 d be- 
ginning at the time of  passive transfer. 
*P <0.05. 
90-100 I~g/ml. This level of drug blocks LTB4 (100 nM)- 
mediated  upregulation  of  the  complement  receptor 
(CDllb/CD18)  on neutrophils  in mouse whole blood by 
>95%.  In addition,  although  rare,  in  cases  where  some 
death was observed in the control groul~, CP-105,696 was 
also able to prevent mortality (data not shown). 
As  shown  in  Table  1,  the  etticacious  effects  of CP- 
105,696 could be observed using three different parameters 
of disease scoring: a decrease in total disease  over the 40-d 
period (area under the curve), a decrease in maximum dis- 
ease severity, and a prolongation of  the day of disease onset. 
The EDs0 for the effects of  CP-105,696 when administered 
immediately after the passive transfer of T  cells was calcu- 
hted to be 8.6 mg/kg based on total disease,  9.5 mg/kg based 
on the day of onset,  and  12.6 mg/kg based on maximum 
disease  severity.  These  protective  effects  of CPo105,696 
were observed by following disease over a 40-d period but 
using  only a  15-d  course  of treatment  and  were  also  re- 
flected  by  a  decrease  in  weight  loss  in  the  CP-105,696- 
treated  group  (data  not  shown).  Similar  results  were  ob- 
tained when treatment with  CP-105,696  was initiated  up 
to 4  d  after the passive transfer of encephalogenic T  cells. 
However, when treatment was initiated  after the  onset of 
symptoms, when high numbers  of eosinophils  are  already 
present,  no  protective  effects  were  observed  (data  not 
shown). 
Histological  examination of  the  brain  and  upper  segment 
of  the spinal  cord of  EAE  animals  revealed cellular  infil- 
trates  consisting primarily  of lymphocytes at the light  mi- 
croscopic level. In contrast, the composition of the cellular 
infiltrate  was  different  in  the  lower  spinal  cord  near  the 
cauda equina, where a large number of eosinophils in addi- 
tion to lymphocytes were observed (Fig. 2  13). In this area 
of the spinal cord, the leukocytes appeared to penetrate the 
neural  tissue  along the  course  of the  supplying vessels.  In 
addition, large numbers ofleukocytes and degenerating ax- 
ons were  observed in the  surrounding nerve roots.  Fig.  3 
illustrates  a section of the lower area of the spinal cord ex- 
amined at the electron microscopic level. The characteristic 
eosinophil  granules  can be  observed,  which  in  many in- 
stances had been released within the extracellular matrix. In 
Figure 2.  Light  microscopy  of  the caudal spinal cord from a naive con- 
trol animal (,4), an animal injected with encephalogenic T cells (/3), and 
an animal injected with encephalogenic  T cells and treated daily with 10 
mg/kg of CP-105,696 (C). Samples were taken 10-14 d after the injec- 
tion of T cells. The histological  sections are representative of three sepa- 
rate experiments. No inflammatory cells were observed surrounding the 
spinal cord (arrowhead)  in the naive controls (A). In contrast, a large influx 
of inflammatory cells were observed surrounding the spinal cord (arrow- 
head) in the vehicle-treated animal injected with encephalogenic T cells 
(B). Some of these cells were ensinophils (auow), which were better ob- 
served in the high magnification insert of the region within the bars. 
Treatment with CP-105,696 (C) resulted in a slight reduction in the T 
cell influx (auowhead), but more importantly, it  resulted in near total 
blockage of the influx of eosinophils. In the high magnification  insert of 
the region within the bars, a representative field of the surrounding T 
cells can be seen. )<280; inset )<840. 
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Figure  4.  Effect  of CP-105,696  on  eosinophil  infiltration  as  deter- 
mined by EPO. Mice were given encephalogenic T  cells intraperitoneally 
and then treated orally with placebo  or CP-105,696.  Spinal cords were 
removed on day  14,  and the level of EPO was determined. The number 
of eosinophils was then calculated from a standard curve.  The detection 
limit based on the dilution of the spinal cord homogenate used was  100 
eosinophils/tissue. The graph represents a summary of five experiments. 
C)  and  electron  (data  not  shown)  microscopic  level.  In 
contrast, the effects of CP-105,696 on lymphocyte infiltra- 
tion were minimal and did not reflect the protective effects 
observed with this agent on paralysis. 
To better quantify the reduction in eosinophil infiltra- 
tion, the amount of EPO  was measured. EPO  levels  are 
detectable at times coincident with the appearance of  paral- 
ysis  in  animals.  When  animals  were  treated  with  CP- 
105,696,  up to a two-log reduction in the level of EPO in 
the  spinal  cord  was  observed  compared  with  vehicle- 
treated animals (Fig.  4).  Animals that did not receive en- 
cephalogenic  cells  had  no  detectable  cellular  infiltration 
into the spinal cords and no detectable EPO levels. 
Figure  3.  Electron microscopy of the caudal spinal cord from animals 
injected with encephalogenic  T  cells and treated with vehicle.  Samples 
were taken 10-14 d after the injection ofT cells. The histological sections 
are representative of three separate experiments. (,t) A representative field 
containing numerous eosinophils releasing their granules (arrowheads) can 
be seen.  ￿  Several axons  (a)  within their encasing myelin sheath 
can be observed. In the longitudinal section of the large fiber (arrowheads), 
numerous eosinophils (e) are present within the myelin sheath, apparently 
replacing the axon.  ￿ 
addition, we  also  observed  eosinophils within apparently 
intact myelinated sheaths replacing the axon (Fig.  3 B) in 
the nerve rootlets surrounding the lower spinal  cord, sug- 
gesting a compromise in integrity upstream from the sec- 
tion.  In  animals treated with  CP-105,696,  a  decrease  in 
eosinophil infiltration was observed at both the light (Fig. 2 
Discussion 
Previous  studies have  indicated the  important role  for 
CD4 + T  cells in the pathogenesis of EAE  (4). Although 
lymphocytes may be responsible for initiating the disease, 
the actual disease  pathology may be mediated by various 
inflammatory cells. We demonstrated that by blocking the 
LTB  4 receptor,  the  development of paralysis  and the re- 
cruitment  of eosinophils  into  the  spinal  cord  was  pre- 
vented.  These  studies indicate that eosinophil infiltration 
was dependent on LTB4 receptor ligation and reveal an im- 
portant role for eosinophils in this disease as illustrated by 
the ability of CP-105,696 to inhibit disease coincident with 
a decrease in eosinophil, but not lymphocyte, numbers in 
the  spinal  cord.  Although  it  could  be  argued  that  CP- 
105,696  is inhibiting additional factors necessary for eosi- 
nophil infiltration, previous studies have indicated the se- 
lectivity for this agent for the LTB  4 receptor, as indicated 
by its inability to inhibit the activity of other G  protein- 
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also has no effect on leukotriene or prostaglandin biosyn- 
thesis  nor  on  IL-l-induced  neutrophil  accumulation  in 
vivo (14). 
There are two possible  ways that LTB  4 might stimulate 
eosinophil infiltration. The first is by direct chemotactic ef- 
fects  on  the  eosinophil  LTB  4  receptor.  LTB4  has  been 
shown  to  induce  eosinophil  chemotaxis  (11),  and  CP- 
105,696  has been demonstrated to block this effect (13). 
However since  LTB  4  is also  chemotactic for neutrophils, 
which were not observed in tissue,  a direct cell-recruiting 
effect is unlikely. The second, perhaps more likely, mecha- 
nism is by stimulating encephalogenic T  cells (7) to release 
eosinophil-chemotactic agents.  Kecently, encephalogenic 
T cells have been shown to express message levels for several 
chemokines (6), including the eosinophil chemoattractants 
macrophage inflammatory protein (MIP) la and KANTES 
(19, 20). Although this mechanism cannot be tested at this 
time since neutralizing antibodies and specific  ELISAs to 
these chemokines are not commercially available,  a report 
has indicated that neutralizing antibodies to MIP-I(x will 
prevent paralysis in EAE (21). 
Although they have been observed in the spinal fluid of 
MS patients (22, 23),  eosinophils have not been previously 
implicated in promoting the  disease  pathology associated 
with EAE. Whereas lymphocytes clearly are present in the 
CNS,  our studies indicate that decreasing eosinophil but 
not lymphocyte infiltration was associated  with inhibition 
of paralysis. EAE is an ascending disease of the CNS such 
that damage occurs first to the lower area, where the my- 
elinated axons supplying the tail and hind limbs originate. 
As such, damage to this area would more closely correlate 
with hind-limb paralysis. Therefore the role of eosinophils 
in EAE may have been underestimated in previous studies, 
which have usually concentrated on the upper areas of the 
spinal  cord and brain (24).  In addition, studies illustrating 
selective inhibition of eosinophil rather than lymphocyte 
recruitment have not been done. A decrease in the number 
of eosinophils shown histologically and enzymatically cor- 
related with a favorable outcome in animals treated with 
CP-105,696.  Our electron microscopic observations dem- 
onstrating  eosinophils  within  the  myelin  sheath  further 
support the hypothesis that these cells may be involved in 
axonal atrophy and paralysis. In addition, as a proof of con- 
cept, an eosinophil-derived neurotoxin has been reported 
to induce EAE-like paralysis when injected into naive ani- 
mals (25). 
In summary, LTB4 receptor ligation was responsible for 
mediating eosinophil influx into the lower spinal cord of 
animals during EAE. These eosinophils are important me- 
diators of paralysis, since treatment with the specific  LTB  4 
receptor antagonist CP-105,696 selectively decreased eosi- 
nophil infiltration into the  CNS  and concomitantly pre- 
vented  disease  symptoms.  The  lack  of effects  of CP- 
105,696  when treatment was initiated after the  onset of 
symptoms and when large numbers of eosinophils are al- 
ready present suggests that continued eosinophil infiltration 
is not important for the progression of disease. Studies are 
in progress to assess the pathological role of eosinophils on 
secondary relapses. 
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